Table 4.
p16 expression in papillary urothelial carcinoma according to stage.
| p16 | Total | ||||||
|---|---|---|---|---|---|---|---|
| Negative | Weak Nuclear | Moderate Nuclear | Strong Nuclear | ||||
| Stage | Stage pT1 | Count | 12 | 0 | 7 | 6 | 25 |
| % within Stage | 48.0% | 0.0% | 28.0% | 24.0% | 100.0% | ||
| % within p16 | 92.3% | 0.0% | 100.0% | 66.7% | 83.3% | ||
| % of Total | 40.0% | 0.0% | 23.3% | 20.0% | 83.3% | ||
| Stage pT2 | Count | 1 | 1 | 0 | 3 | 5 | |
| % within Stage | 20.0% | 20.0% | 0.0% | 60.0% | 100.0% | ||
| % within p16 | 7.7% | 100.0% | 0.0% | 33.3% | 16.7% | ||
| % of Total | 3.3% | 3.3% | 0.0% | 10.0% | 16.7% | ||
| Total | Count | 13 | 1 | 7 | 9 | 30 | |
| % within Stage | 43.3% | 3.3% | 23.3% | 30.0% | 100.0% | ||
| % within p16 | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ||
| % of Total | 43.3% | 3.3% | 23.3% | 30.0% | 100.0% | ||
p value = 0.03.